10-Q: Biomerica Reports Q3 2026 Results Amidst Revenue Decline

Biomerica, Inc. announced its third-quarter fiscal year 2026 financial results, reporting a 12% decrease in net sales compared to the prior year, primarily due to lower contract manufacturing revenue, while also highlighting progress in new product development and a continued focus on liquidity.

Summary

• Biomerica reported net sales of $987,000 for the three months ended February 28, 2026, a decrease of 12% from $1,119,000 in the same period last year.
• For the nine months ended February 28, 2026, net sales were $3,578,000, down 22% from $4,562,000 in the prior year.
• The company experienced a net loss of $1,312,000 for the three months ended February 28, 2026, compared to a net loss of $1,163,000 in the prior year.
• For the nine months ended February 28, 2026, the net loss was $2,630,000, compared to $3,429,000 in the prior year.
• Cash and cash equivalents decreased to $1,336,000 as of February 28, 2026, from $2,399,000 as of May 31, 2025.
• The company has a shelf registration statement allowing for up to $20 million in common stock offerings and has utilized an at-the-market (ATM) offering, raising $1,455,000 in net proceeds during the nine months ended February 28, 2026.
• The company received FDA clearance for hp+detect and announced a national Medicare payment rate of $300 for inFoods IBS, representing steps towards broader market access.
• Significant cost-cutting measures have been initiated to extend the cash runway.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative filing due to declining revenues, increased net loss, and significant going concern risks, despite some positive developments in product clearance and reimbursement efforts.

Positives

• The company received FDA clearance for its hp+detect diagnostic test.
• A national Medicare payment rate of $300 was established for the inFoods IBS product, a positive step towards reimbursement and market access.
• Net proceeds of $1,455,000 were raised through an at-the-market (ATM) offering during the nine months ended February 28, 2026, strengthening liquidity.
• Over-the-counter product sales increased by 16% for the three months ended February 28, 2026, compared to the prior year.
• Research and development expenses decreased by 18% for the three months and 24% for the nine months ended February 28, 2026, reflecting a transition from development to commercialization.
• The company received its first commercial order for hp+detect from a large European clinical laboratory chain.

Negatives

• Consolidated net sales decreased by 12% for the three months ended February 28, 2026, and by 22% for the nine months ended February 28, 2026, compared to the prior year.
• Contract manufacturing revenue significantly decreased by 48% for the three months and 42% for the nine months ended February 28, 2026.
• The company reported a net loss of $1,312,000 for the three months ended February 28, 2026, an increase from $1,163,000 in the prior year.
• Cash and cash equivalents decreased from $2,399,000 to $1,336,000 during the period.
• The company's working capital decreased from $3,135,000 to $2,562,000.
• The company acknowledges substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows from operations.
• Cost of sales as a percentage of net sales increased to 104% for the three months and 88% for the nine months ended February 28, 2026, indicating pressure on gross margins.
• Selling, general and administrative expenses increased by 6% for the three months ended February 28, 2026, despite declining sales.

Risks

• The company's ability to raise additional capital and continue as a going concern is a significant risk.
• The accuracy of expense estimates, future revenue projections, capital requirements, and the need for additional financing are subject to uncertainty.
• Competition from companies with greater financial, technical, and marketing resources poses a risk.
• Obtaining and maintaining government or regulatory certification for products in various regions presents a challenge.
• Maintaining sales relationships with key distributors is crucial and carries inherent risks.
• Global economic and political developments, including inflation, interest rates, wars, and economic slowdowns, could negatively impact the business.
• Third parties asserting intellectual property infringement claims could adversely affect the company.
• Compliance with numerous laws and regulations, which may be modified, presents ongoing risks.
• Product recalls, liability claims, or harm to patients or users of products could lead to material adverse effects.
• The ability to retain key personnel and attract qualified professionals is critical.
• The company's future viability depends on successful execution of strategic plans, securing near-term financing, and achieving profitable operations.
• The company is actively pursuing strategies to increase sales, reduce expenses, sell non-core assets, and seek additional financing, but there is no assurance these efforts will be successful or sufficient.

Future Outlook

The company is actively pursuing strategies to increase sales, reduce expenses, sell non-core assets, and seek additional financing through debt or equity to address capital needs and sustain operations. Management believes its current cash and cash equivalents are insufficient to meet operating cash requirements and strategic growth objectives for the next twelve months. The company's future viability depends on the successful execution of its strategic plans, securing additional near-term financing, and achieving profitable operations.

Management Comments

• "Our future viability depends on the successful execution of our strategic plans, securing additional near-term financing, and achieving profitable operations."
• "Based on our current operating plan, we believe that our existing cash and cash equivalents will be insufficient to fund our operations and meet our obligations for the next twelve months from the issuance date of these financial statements."
• "We intend to use the net proceeds from any funds raised through the 2024 ATM Offering for general corporate purposes, including, but not limited to, sales and marketing activities, clinical studies and product development, acquisitions of assets, businesses, companies, or securities, capital expenditures, and working capital needs."
• "The establishment of a reimbursement rate does not guarantee coverage, utilization, or payment, management believes it represents an important step toward broader market access and provides a foundation for potential increased patient access and initial claims activity."

Industry Context

StockSavvy.ai notes that Biomerica's performance reflects challenges common in the early-stage diagnostic and biotechnology sectors, including long development cycles, regulatory hurdles, and the need for significant capital investment. The company's focus on diagnostic-guided therapy (DGT) aligns with a growing trend towards personalized medicine, but commercialization and reimbursement remain critical success factors.

Comparison to Industry Standards

• Biomerica's revenue decline of 22% for the nine-month period is significantly worse than the average growth seen in the broader medical device and diagnostics industry, which has generally experienced moderate to strong growth.
• The company's net loss of $2.63 million for the nine-month period, while reduced from the prior year, indicates continued unprofitability, which is common for early-stage biotech firms but contrasts with established, profitable players in the sector.
• The company's cash burn rate and concerns about its ability to continue as a going concern are critical issues. Many companies in this sector rely on continuous access to capital markets, but Biomerica's current situation suggests a more challenging funding environment compared to well-capitalized competitors.
• The establishment of a Medicare reimbursement rate for inFoods IBS, while positive, is a single step. Broader adoption and reimbursement from private payers are necessary to achieve commercial success comparable to established diagnostic tests in the market.

Management Changes

Legal Proceedings

• As of February 28, 2026, there were no material legal proceedings pending.

Stakeholder Impact

• Shareholders: Potential dilution from ongoing ATM offerings, continued financial losses, and uncertainty regarding the company's ability to continue as a going concern may negatively impact share value.
• Employees: The company's financial situation and cost-cutting measures could lead to uncertainty regarding job security and future growth opportunities.
• Creditors: The company's going concern issues and need for financing may impact its ability to meet its obligations.
• Customers/Distributors: Continued focus on new product launches like inFoods IBS and hp+detect, alongside efforts to secure reimbursement, could lead to increased product availability and adoption if successful.

Next Steps

• Continue to pursue U.S. government payment or reimbursement for the inFoods IBS product through the Medicare system.
• Pursue reimbursement with private payer insurance companies as Medicare reimbursement becomes established.
• Evaluate options for the lease of corporate headquarters, including potential renewal or relocation.
• Actively pursue strategies to increase sales, reduce expenses, sell non-core assets, and seek additional financing.
• Continue to market hp+detect to large end-customer laboratories and pursue commercial adoption.
• Evaluate and work with distribution, partnership, and licensing opportunities with U.S. companies for inFoods IBS.

Key Dates

Recommendation

While the company faces significant financial challenges, including declining revenues and going concern risks, the progress in product development (FDA clearance for hp+detect) and the establishment of a Medicare reimbursement rate for inFoods IBS offer some potential upside. The ongoing ATM offering provides liquidity but also dilutes existing shareholders. Given the mixed signals, a 'hold' recommendation is appropriate, pending further clarity on commercialization success and improved financial stability.

Keywords

Biomerica, 10-Q, Quarterly Report, Diagnostic Products, Medical Devices, Financial Results, Revenue, Net Loss, Cash Flow, Going Concern, ATM Offering, inFoods IBS, hp+detect, Medicare Reimbursement, Biotechnology